Ishikawa O, Kubota Y, Miyachi Y
Department of Dermatology, Gunma University School of Medicine, Maebashi, Japan.
Eur J Pharmacol. 1998 Feb 26;344(1):95-8. doi: 10.1016/s0014-2999(97)01575-6.
Prostaglandin E1 has been clinically used in a variety of vascular occlusive diseases. We investigated the in vitro effect of prostaglandin E1 on the synthesis of tumor necrosis factor-alpha, interleukin-1, interleukin-6, interleukin-10 and transforming growth factor beta by human peripheral blood mononuclear cells stimulated with lipopolysaccharides. Prostaglandin E1 significantly suppressed both the mRNA expression and the production of tumor necrosis factor-alpha and interleukin-10 by lipopolysaccharides-stimulated peripheral blood mononuclear cells in a dose-dependent manner (1 x 10(-6)-1 x 10(-8) M). Since tumor necrosis factor-alpha is a potent proinflammatory cytokine involved in certain inflammatory diseases, our findings suggest the possibility to expand the clinical application of prostaglandin E1.
前列腺素E1已在临床上用于多种血管闭塞性疾病。我们研究了前列腺素E1对脂多糖刺激的人外周血单核细胞合成肿瘤坏死因子-α、白细胞介素-1、白细胞介素-6、白细胞介素-10和转化生长因子β的体外作用。前列腺素E1以剂量依赖性方式（1×10^(-6)-1×10^(-8) M）显著抑制脂多糖刺激的外周血单核细胞中肿瘤坏死因子-α和白细胞介素-10的mRNA表达及产生。由于肿瘤坏死因子-α是参与某些炎症性疾病的一种强效促炎细胞因子，我们的研究结果提示了扩大前列腺素E1临床应用的可能性。
